Alopecia totalis

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Alopecia totalis
Classification and external resources

A woman with alopecia totalis.
ICD-10 L63.0

Alopecia totalis is the loss of all head hair. Its causes are unclear, but it is currently believed to be an autoimmune disorder. Stress is sometimes thought to be a contributor in alopecia areata. However, many people leading relatively stress-free lives experience the syndrome.

Contents

[edit] Treatment

Methotrexate and corticosteroids are proposed treatments.[1]


On the date of 29/06/2006 Diphenylcyclopropenone was granted orphan designation by the European Medicines agency for the treatment of Alopecia Totalis and the Treatment of Alopecia universalis. Please follow the link for full details; community register of orphan medicinal products Orphan designation is not market approval for a product, but approval given to a pharmaceutical company to develop a product. Below is the European medicines agency definition of orphan designation;

A designation from the European Medicines Agency's Committee on Orphan Medicinal Products (COMP) permits a pharmaceutical company to benefit from incentives from the European Union to develop a medicine for a rare disease such as a genetic disorder or a rare cancer. A large number of these diseases affect children and newborn babies. Once orphan designation is granted a medicine may be developed by the pharmaceutical company. for further information on orphan drugs' please follow this link; orphan drug designation

[edit] References

  1. ^ Joly P (2006). "The use of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia totalis or universalis". J. Am. Acad. Dermatol. 55 (4): 632–6. doi:10.1016/j.jaad.2005.09.010. PMID 17010743. 

[edit] See also

[edit] External links


Personal tools
Namespaces
Variants
Actions
Navigation
Interaction
Toolbox
Print/export
Languages